Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Mallinckrodt
Harvard Business School
Colorcon
Baxter

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for FG-3019

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug FG-3019?

FG-3019 is an investigational drug.

There have been 14 clinical trials for FG-3019. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2019.

The most common disease conditions in clinical trials are Fibrosis, Pulmonary Fibrosis, and Pancreatic Neoplasms. The leading clinical trial sponsors are FibroGen, Jonsson Comprehensive Cancer Center, and [disabled in preview].

There are eight US patents protecting this investigational drug and sixty-four international patents.

Recent Clinical Trials for FG-3019
TitleSponsorPhase
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Gemcitabine and Nab-paclitaxel) in Locally Advanced Pancreatic CancerFibroGenPhase 3
Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary FibrosisFibroGenPhase 3
Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic CancerJonsson Comprehensive Cancer CenterN/A

See all FG-3019 clinical trials

Clinical Trial Summary for FG-3019

Top disease conditions for FG-3019
Top clinical trial sponsors for FG-3019

See all FG-3019 clinical trials

US Patents for FG-3019

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
FG-3019   Start Trial Aerosol pirfenidone and pyridone analog compounds and uses thereof Avalyn Pharma Inc. (Seattle, WA)   Start Trial
FG-3019   Start Trial Method of treating pancreatic cancer ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
FG-3019   Start Trial Inhibitors of endoglin activity for the treatment of fibrosis Tufts Medical Center, Inc. (Boston, MA)   Start Trial
FG-3019   Start Trial Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
FG-3019   Start Trial Method for decreasing depression-like behavior with connective tissue growth factor (CTGF) inhibitor The Board of Trustees of the Leland Stanford Junior University (Stanford, CA)   Start Trial
FG-3019   Start Trial Methods of treating pancreatic cancer ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
FG-3019   Start Trial Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for FG-3019

Drugname Country Document Number Estimated Expiration Related US Patent
FG-3019 Australia 2012212269 2031-01-31   Start Trial
FG-3019 Australia 2013207409 2031-01-31   Start Trial
FG-3019 Australia 2013295800 2031-01-31   Start Trial
FG-3019 Australia 2016213708 2031-01-31   Start Trial
FG-3019 Australia 2018206852 2031-01-31   Start Trial
FG-3019 Canada 2824432 2031-01-31   Start Trial
FG-3019 Canada 2858245 2031-01-31   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Baxter
Moodys
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.